NMD Pharma Reports Positive Phase 2a Ignaseclant Data in CMT
AARHUS, Denmark, June 17, 2026 NMD Pharma A/S announced new positive clinical findings from its Phase 2a SYNAPSE-CMT study...
AI drug discovery Alzheimer’s Disease artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biotechnology Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology oncology innovation Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory compliance targeted therapy
AARHUS, Denmark, June 17, 2026 NMD Pharma A/S announced new positive clinical findings from its Phase 2a SYNAPSE-CMT study...
